Search
+
    SEARCHED FOR:

    STRONG BINDING TO HUMAN CELLS

    Ola Electric says demand outstrips supply, targets 25,000 vehicles in December

    Ola Electric Mobility is experiencing high demand for its electric two-wheelers, causing supply constraints. The company plans to ramp up production to approximately 25,000 vehicles by December. Despite these plans, recent losses were reported along with a decline in consolidated revenue from operations. Ola Electric has significantly reduced its borrowings and expects to generate free cash flow soon.

    Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment

    Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.

    India may open doors to multinational pharma firms for first-in-human Phase I trials

    India is considering modifications to its pharmaceutical regulatory framework to attract multinational companies for clinical trials. Discussions have commenced regarding allowing these companies to conduct Phase I trials in India. Authorities aim to enhance India's appeal for global drug innovation and development. Strengthening manufacturing compliance over the last two years has also been part of the plan.

    Centre bans export of Li-ion battery waste, scrap to boost domestic recycling and critical mineral recovery

    India has imposed an immediate ban on the export of lithium-ion battery black mass to strengthen its local recycling ecosystem. This decision aims to enhance domestic recovery of critical minerals, such as lithium and cobalt, which are vital for technology and energy sectors. The prohibition will ensure that battery waste generated in India is processed locally and improves utilization of recycling capacities.

    Why scientists call PJ.2.1 a ‘jump’ variant: The COVID strain that arrived with dozens of mutations at once and spreads by gripping your cells more tightly

    A new variant of SARS-CoV-2, named PJ.2.1, was detected in Canada and has spread globally. It has over 25 mutations in its spike protein, which enhance its binding to human cells. Researchers are observing its spread in countries like the US, Spain, and Australia among others. Currently, there is no evidence linking PJ.2.1 to increased severity of illness or hospitalization.

    Dario Amodei says AI could make cancer, Alzheimer’s ‘relics of the past’ in less than a decade as Anthropic expands AI-driven drug discovery push

    Anthropic is collaborating with several pharmaceutical companies to utilize AI in drug development processes. These partnerships aim to improve the efficiency of drug discovery, addressing complex challenges in medical research. Notable projects include redesigning therapeutic molecules and accelerating antibody designs for various diseases. Anthropic has also initiated its own research on rare childhood muscular dystrophies, targeting potential clinical trials by late 2028.

    The Economic Times
    BACK TO TOP